Can Biomarkers Be Used to Identify Patients Who Are Most Likely to Benefit from Adenosine-Pathway Targeted Cancer Immunotherapy?

Time: 12:10 pm
day: Day One


• Discussing the role of adenosine in the tumor microenvironment

• Divulging biomarkers as surrogates for the presence of adenosine

• Highlighting the A2AR as a biomarker for response to inupadenant in iTeos clinical trials